In a survey that evaluated prescribing decisions, physicians preferred extended-release (ER) monotherapy for treating patients with attention-deficit/hyperactivity disorder (ADHD), according to results published in the Journal of Attention Disorders. Physicians specifically cited duration of effect and tolerability as the rationale for their ER monotherapy preference.